KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Non-Current Liabilities (2016 - 2025)

Nektar Therapeutics has reported Total Non-Current Liabilities over the past 16 years, most recently at $181.9 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $181.9 million for Q4 2025, down 22.86% from a year ago — trailing twelve months through Dec 2025 was $181.9 million (down 22.86% YoY), and the annual figure for FY2025 was $181.9 million, down 22.86%.
  • Total Non-Current Liabilities for Q4 2025 was $181.9 million at Nektar Therapeutics, down from $211.2 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for NKTR hit a ceiling of $471.8 million in Q3 2021 and a floor of $181.9 million in Q4 2025.
  • Median Total Non-Current Liabilities over the past 5 years was $285.0 million (2023), compared with a mean of $316.6 million.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 41.1% in 2021 and later decreased 27.17% in 2023.
  • Nektar Therapeutics' Total Non-Current Liabilities stood at $410.0 million in 2021, then dropped by 17.94% to $336.4 million in 2022, then dropped by 22.0% to $262.4 million in 2023, then fell by 10.11% to $235.9 million in 2024, then decreased by 22.86% to $181.9 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $181.9 million (Q4 2025), $211.2 million (Q3 2025), and $226.1 million (Q2 2025) per Business Quant data.